Safety profile of tasocitinib (cp-690,550)-based cni-free regimens in de novo kidney transplant patients in a dose/exposure-finding phase 2b study: results of a 6-month interim analysis
Transplantation（2010）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要